Using RWE to Monitor Long Term Effectiveness Post Launch The adoption of Real-World Evidence (RWE) in pharmaceuticals has accelerated in recent years, particularly after product launch. Regulatory bodies such as the US FDA have recognized the potential of RWE to enhance decision-making regarding long-term effectiveness, particularly in scenarios of label expansion, safety signals, and post-marketing commitments. This article provides a detailed, step-by-step guide on how to effectively utilize RWE to monitor long-term effectiveness, catering to professionals in regulatory affairs, biostatistics, health economics and outcomes research (HEOR), and data standards in the pharma and medtech industries. Understanding RWE and Its Regulatory…

RWE Approaches When Conducting New RCTs Is Not Feasible or Ethical The implementation of real-world evidence (RWE) in the regulatory framework for label expansion, evaluation of safety signals, and adherence to post-marketing requirements is essential in the current pharmaceutical landscape. Traditional randomized controlled trials (RCTs), while the gold standard for clinical evidence, may not always be feasible or ethical, particularly in specific populations or when dealing with rare diseases. In this guide, we will explore the structured approach to leveraging RWE to meet regulatory expectations and ensure compliance in the US, UK, and EU contexts. Understanding RWE and Its Regulatory…

Communicating RWE Driven Label Updates to Clinicians and Payers The landscape of pharmaceutical and medical device regulation is constantly evolving, especially with the growing emphasis on real-world evidence (RWE). This comprehensive guide outlines step-by-step approaches to communicating RWE-driven label updates, focusing on safety signals, post-marketing commitments, and label expansion. Professionals in regulatory affairs, biostatistics, health economics and outcomes research (HEOR), and data standards must engage with this evolving framework to ensure that updates are both compliant and clinically meaningful. 1. Understanding Real-World Evidence (RWE) Real-world evidence is defined by the Food and Drug Administration (FDA) as the clinical evidence derived…

Data Curation Workflows That Enhance RWE Reliability and Auditability In the evolving landscape of regulatory science, the quality and integrity of real-world data (RWD) have become paramount for the success of health interventions and regulatory submissions. Accurate data curation workflows improve the reliability and auditability of RWD, making it essential for pharmaceutical and medtech professionals to understand how to manage these processes effectively. This tutorial outlines a comprehensive step-by-step guide designed to help regulatory, biostatistics, Health Economics and Outcomes Research (HEOR), and data standards professionals enhance their data curation practices in accordance with U.S. FDA regulations. Understanding Real-World Data Quality,…

Handling Misclassification and Measurement Error in Claims and EHR Data Introduction to Misclassification and Measurement Error In the domain of real-world evidence (RWE), the integrity and quality of real-world data (RWD) are paramount. Misclassification and measurement errors can significantly compromise the validity of research outcomes derived from claims data and electronic health records (EHR). These inaccuracies not only pose challenges for regulatory submissions but can also lead to biased conclusions in health economics and outcomes research (HEOR). This article aims to provide a comprehensive, step-by-step tutorial on handling misclassification and measurement error in claims and EHR data, specifically focusing on…

Detecting and Mitigating Selection Bias in Observational RWE Studies Detecting and Mitigating Selection Bias in Observational RWE Studies As real-world evidence (RWE) gains acceptance in regulatory decision-making, understanding the intricacies of data quality, integrity, and bias management becomes paramount. This tutorial aims to provide a comprehensive overview of detecting and mitigating selection bias in observational RWE studies, focusing on regulatory expectations and best practices in the US, UK, and EU. The goal is to equip regulatory professionals, biostatisticians, and data managers with the necessary tools to ensure the reliability of RWE in supporting healthcare decisions. 1. Understanding Selection Bias in…

Frameworks for assessing RWD fitness for purpose in RWE programs Frameworks for Assessing RWD Fitness for Purpose in RWE Programs Real-world data (RWD) has become paramount in informing healthcare decisions and enhancing the understanding of treatment effectiveness and safety. However, ensuring the quality, integrity, and management of bias in RWD is crucial for its effective utilization. This comprehensive tutorial provides a step-by-step guide for assessing the fitness for purpose of RWD within real-world evidence (RWE) programs, with a focus on regulatory compliance in the United States. The tutorial also references methodologies applicable in the UK and EU when relevant. 1….

Quality and Integrity Pillars for Regulatory Grade Real World Data Sets As the integration of real-world data (RWD) into clinical research and regulatory decision-making continues to expand, the importance of maintaining data quality and integrity cannot be overstated. Regulatory bodies like the U.S. Food and Drug Administration (FDA) have emphasized the need for robust quality frameworks when utilizing RWD for submissions and regulatory decisions. This comprehensive tutorial aims to provide a step-by-step guide for professionals in the pharmaceutical and medtech industries on how to ensure the quality and integrity of real-world data sets, focusing on key aspects such as bias…

Balancing Data Richness with Privacy and De-identification Constraints In the realm of clinical research, particularly concerning real-world data (RWD), there is an ongoing interplay between the richness of data and the imperative to maintain privacy. As healthcare data becomes more extensive and varied, the challenge arises to ensure data quality and integrity while effectively managing potential biases. This tutorial will guide you through the complexities of real-world data quality integrity bias management, focusing on the U.S. FDA regulations and the best practices to foster compliance. We will delve into the nuances of RWD fitness for purpose, selection bias, misclassification, data…

Case Examples of RWE Rejected Due to RWD Quality Concerns In recent years, real-world evidence (RWE) has gained prominence in regulatory decision-making processes, steering the pharmaceutical and medical device industries toward evidence-based practices. However, the use of real-world data (RWD) necessitates an unwavering commitment to data quality, integrity, and bias management. This article presents a comprehensive tutorial on RWE, emphasizing case examples where RWD submissions were rejected due to quality concerns, thereby providing regulatory, biostatistics, health economics and outcomes research (HEOR), and data standards professionals with critical insights into fitness for purpose in RWD. Understanding Real-World Evidence and Real-World Data…